000049000 000__ 01415cam\a22003495i\4500
000049000 001__ 49000
000049000 003__ SzGeWIPO
000049000 005__ 20240322214758.0
000049000 006__ m    eo  d        
000049000 007__ cr bn |||m|||a
000049000 008__ 240321s2010\\\\enk\\\\\\\\\\u000\0\eng\d
000049000 022__ $$a2044-7175
000049000 035__ $$a(OCoLC)1427546079
000049000 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000049000 041__ $$aeng
000049000 043__ $$ae-uk---
000049000 084__ $$aGB 139
000049000 24500 $$aNot all pharma IP law is transferable.
000049000 264_1 $$aLondon, England:$$bInforma, U.K.$$c2010.
000049000 300__ $$aGB 139 May 2010 ;$$c[28] cm
000049000 336__ $$atext$$2rdacontent
000049000 337__ $$acomputer$$2rdamedia
000049000 338__ $$aonline resource$$bcr$$2rdacarrier
000049000 520__ $$aThe battle for supremacy between Europe and the US in the fields of pharmaceutical R&D and innovation has pointlessly flared up once again. A recently published survey by international intellectual property specialists Marks & Clerk indicates that the US IP system is viewed as being more favourable to innovation and that President Obama's recently passed healthcare reforms are proving to be increasingly palatable for big pharma.
000049000 650_0 $$aIntellectual property.
000049000 650_0 $$aPharmaceuticals.
000049000 650_0 $$aIntellectual property$$zUnited States.
000049000 7001_ $$aFaraz Kermani, Scrip,$$eauthor.
000049000 903__ $$aIntellectual Property Magazine
000049000 942__ $$cART$$jGB 139 May 2010$$2ddc
000049000 980__ $$aBIB
000049000 999__ $$c28508$$d28508